Compare EE & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EE | PHAR |
|---|---|---|
| Founded | 2003 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2022 | 2020 |
| Metric | EE | PHAR |
|---|---|---|
| Price | $39.35 | $11.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $39.20 | $38.33 |
| AVG Volume (30 Days) | ★ 324.2K | 19.9K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.96% | N/A |
| EPS Growth | ★ 0.79 | N/A |
| EPS | ★ 0.75 | N/A |
| Revenue | ★ $1,228,263,000.00 | N/A |
| Revenue This Year | $23.59 | $10.04 |
| Revenue Next Year | $24.37 | $2.51 |
| P/E Ratio | ★ $52.48 | $3,041.22 |
| Revenue Growth | ★ 44.26 | N/A |
| 52 Week Low | $23.23 | $9.62 |
| 52 Week High | $43.18 | $21.34 |
| Indicator | EE | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 61.62 | 48.89 |
| Support Level | $32.03 | $11.88 |
| Resistance Level | $40.00 | $13.51 |
| Average True Range (ATR) | 1.47 | 0.59 |
| MACD | 0.27 | 0.13 |
| Stochastic Oscillator | 89.59 | 56.74 |
Excelerate Energy Inc. offers comprehensive LNG solutions by providing integrated services throughout the LNG value chain. The company delivers a full range of regasification services, including Floating Storage and Regasification Units (FSRUs), infrastructure development, and the supply of LNG and natural gas. With operational presence in several countries - Argentina, Bangladesh, Brazil, Finland, Germany, Pakistan, the United Arab Emirates (UAE), and the United States. The company generates revenue through Terminal Services, as well as from LNG, gas, and power. These revenues are derived from its vertically integrated activities in LNG sourcing, transportation, regasification, and power generation.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.